A Phase 1 interventional study of TAK-491 and TAK-491 placebo in Healthy Volunteer, sponsored by Takeda. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-05.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the pharmacokinetics and safety of single- and multiple-dose of TAK-491 in healthy Chinese participants.
The drug being tested in this study is called TAK-491. TAK-491 is being tested to treat people who have hypertension. This study will look at the pharmacokinetics of TAK-491 in Chinese participants who take TAK-491.
The study will enroll approximately 64 participants.
The first 16 enrolled participants have been randomly assigned (by chance, like flipping a coin) to 1 of the 2 treatment groups:
All participants will be asked to take 1 tablet at the same time on Day 1 and Day 4 to 10 during the study.
The following 48 randomized participants will be randomly assigned (by chance, like flipping a coin) to 1 of the 3 treatment groups:
All participants will be asked to take two tablets at the same time on Day 1 and Day 4 to 10 during the study.
This single-center trial will be conducted in China. The overall time to participate in this study is approximately 52 days. Participants will be admitted in the clinic for the first 12 days, and will be contacted by telephone 14 days after last dose of study drug for a follow-up assessment.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-491 40 milligram (mg), tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
Drug: TAK-491
TAK-491 80 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
Drug: TAK-491
TAK-491 40 mg, tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
Drug: TAK-491 · Drug: TAK-491 placebo
TAK-491 80 mg, tablet, orally, once daily and TAK-491 40 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
Drug: TAK-491 · Drug: TAK-491 placebo
TAK-491 40 mg placebo-matching tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10.
Drug: TAK-491 placebo
TAK-491 tablets
Also known as: Azilsartan medoxomil, Edarbi
TAK-491 placebo-matching tablets
Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10
Time frame: Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10
Time frame: Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10
Time frame: Day 10 pre-dose and at multiple time points (up to 24 hours) post-dose
Terminal Phase Elimination Half-life (T1/2) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Participants took part in the study at 1 investigative site in China from 17 November 2015 to 17 March 2017.
| Milestone | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: Placebo | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg |
|---|---|---|---|---|---|
| Started | 8 | 8 | 0 | 0 | 0 |
| Completed | 8 | 8 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: Placebo | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 16 | 16 | 16 |
| Completed | 0 | 0 | 15 | 16 | 15 |
| Not completed | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 |
| nanogram per milliliter (ng/mL) | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg |
|---|---|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 2877 ± 25.0 | 6250 ± 20.5 | 2444 ± 22.5 | 5460 ± 30.4 |
| ng/mL | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg |
|---|---|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 3070 ± 4.6 | 6019 ± 29.5 | 2628 ± 23.3 | 6226 ± 19.9 |
| hour | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg |
|---|---|---|---|---|
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 3.03 (2.00 to 6.00) | 2.50 (2.00 to 4.00) | 3.00 (2.00 to 6.03) | 2.50 (1.00 to 6.00) |
| hour | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg |
|---|---|---|---|---|
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 3.00 (1.00 to 4.00) | 2.52 (2.00 to 6.00) | 3.49 (1.98 to 5.98) | 2.00 (1.98 to 6.00) |
| hour*nanogram per milliliter (h*ng/mL) | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg |
|---|---|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 25905 ± 27.3 | 50359 ± 12.1 | 23439 ± 22.6 | 45698 ± 32.1 |
| h*ng/mL | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg |
|---|---|---|---|---|
| AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for TAK-536 (the Active Moiety Derived From TAK-491) on Day 10 | 25087 ± 21.5 | 45320 ± 14.7 | 21872 ± 19.1 | 47993 ± 31.8 |
| hour | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg |
|---|---|---|---|---|
| Terminal Phase Elimination Half-life (T1/2) for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 | 11.18 ± 19.4 | 10.18 ± 24.1 | 11.12 ± 16.9 | 11.10 ± 18.9 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Day 40). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label: TAK-491 40 mg | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Open Label: TAK-491 80 mg | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Double-blind: Placebo | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| Double-blind: TAK-491 40 mg | 0/16 (0%) | 0/16 (0%) | 4/16 (25%) |
| Double-blind: TAK-491 80 mg | 0/16 (0%) | 0/16 (0%) | 10/16 (62.5%) |
| Event | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: Placebo | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg |
|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/8 | 2/8 | 1/16 | 0/16 | 4/16 |
| Aspartate aminotransferase increasedInvestigations | 0/8 | 0/8 | 1/16 | 0/16 | 4/16 |
| Transaminases increasedInvestigations | 2/8 | 2/8 | 0/16 | 0/16 | 0/16 |
| Blood triglycerides increasedInvestigations | 0/8 | 0/8 | 1/16 | 1/16 | 3/16 |
| Blood creatine phosphokinase increasedInvestigations | 1/8 | 0/8 | 0/16 | 0/16 | 2/16 |
| DizzinessNervous system disorders | 1/8 | 0/8 | 0/16 | 2/16 | 0/16 |
| VertigoEar and labyrinth disorders | 0/8 | 0/8 | 0/16 | 1/16 | 0/16 |
| AstheniaGeneral disorders | 0/8 | 0/8 | 0/16 | 0/16 | 1/16 |
| NasopharyngitisInfections and infestations | 0/8 | 0/8 | 1/16 | 0/16 | 1/16 |
| Gastrointestinal viral infectionInfections and infestations | 0/8 | 0/8 | 0/16 | 0/16 | 1/16 |
The randomized set included all participants who were randomized.
| Age, Continuous(years) | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: Placebo | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 28.8 ± 4.40 | 30.3 ± 4.98 | 33.0 ± 5.07 | 27.4 ± 4.19 | 29.7 ± 5.63 | 29.9 ± 5.19 |
| Sex: Female, Male(Participants) | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: Placebo | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 3 | 1 | 1 | 3 | 11 |
| Male | 5 | 5 | 15 | 15 | 13 | 53 |
| Race (NIH/OMB)(Participants) | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: Placebo | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 8 | 8 | 16 | 16 | 16 | 64 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: Placebo | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg | Total |
|---|---|---|---|---|---|---|
| China | 8 | 8 | 16 | 16 | 16 | 64 |
| Height(centimeter (cm)) | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: Placebo | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 169.9 ± 6.66 | 165.3 ± 6.36 | 171.0 ± 6.07 | 170.4 ± 5.80 | 171.9 ± 6.75 | 170.2 ± 6.41 |
| Weight(kilogram (kg)) | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: Placebo | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 66.23 ± 4.785 | 59.83 ± 4.951 | 64.09 ± 6.012 | 64.79 ± 7.916 | 65.69 ± 6.934 | 64.40 ± 6.619 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: Placebo | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 22.96 ± 1.289 | 21.94 ± 1.707 | 21.89 ± 1.143 | 22.23 ± 1.703 | 22.16 ± 1.109 | 22.18 ± 1.382 |
| Smoking classification(Participants) | Open Label: TAK-491 40 mg | Open Label: TAK-491 80 mg | Double-blind: Placebo | Double-blind: TAK-491 40 mg | Double-blind: TAK-491 80 mg | Total |
|---|---|---|---|---|---|---|
| Never smoked | 8 | 8 | 14 | 14 | 13 | 57 |
| Current smoker | 0 | 0 | 0 | 0 | 0 | 0 |
| Ex-smoker | 0 | 0 | 2 | 2 | 3 | 7 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Mar 2017, 15 months.
Results were first posted in Feb 2020, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azilsartan medoxomil